API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded
https://www.fiercepharma.com/marketing/opdivo-repatha-and-lynparza-likely-among-china-s-2018-blockbuster-nods-report
http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx
http://www.fiercepharma.com/pharma-asia/japan-s-pmda-reviews-hep-b-risk-link-to-hep-c-therapies
http://www.fiercepharmaasia.com/story/bms-phiii-hep-c-combo-results-milestone-china-plans/2016-02-22
http://www.fiercepharmaasia.com/story/bms-gets-leg-china-hep-c-race-phi-daklinza/2015-11-18
http://www.fiercepharma.com/story/abbvie-moves-closer-japans-crowded-hep-c-field-priority-review-nod/2015-04-16
http://www.fiercepharmaasia.com/story/japan-pharma-market-track-80-billion-mark-2020-obstacles-seen/2015-03-31